(PharmaNewsWire.Com, June 10, 2017 ) Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child’s sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Lyme Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Lyme Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Lyme Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lyme Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Lyme Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Number of Products under Development for Autism, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Autism - Pipeline by Addex Therapeutics Ltd, H1 2017 Autism - Pipeline by Aequus Pharmaceuticals Inc, H1 2017 Autism - Pipeline by AgeneBio Inc, H1 2017 Autism - Pipeline by Anima Biotech Ltd, H1 2017 Autism - Pipeline by APeT Holding BV, H1 2017 Autism - Pipeline by Avanir Pharmaceuticals Inc, H1 2017 Autism - Pipeline by BioCrea GmbH, H1 2017 Autism - Pipeline by BioHealthonomics Inc, H1 2017 Autism - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017 Autism - Pipeline by Confluence Pharmaceuticals LLC, H1 2017 Autism - Pipeline by Coronis NeuroSciences Ltd, H1 2017 Autism - Pipeline by Curemark LLC, H1 2017 Autism - Pipeline by DRI Biosciences Corp, H1 2017 Autism - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Autism - Pipeline by GW Pharmaceuticals Plc, H1 2017 Autism - Pipeline by Heptares Therapeutics Ltd, H1 2017 Autism - Pipeline by Immuron Ltd, H1 2017 Autism - Pipeline by Intra-Cellular Therapies Inc, H1 2017 Autism - Pipeline by Leading BioSciences Inc, H1 2017 Autism - Pipeline by MedDay SA, H1 2017 Autism - Pipeline by Omeros Corp, H1 2017 Autism - Pipeline by OptiNose US Inc, H1 2017 Autism - Pipeline by Sumitomo Chemical Co Ltd, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Autism - Dormant Projects, H1 2017 Autism - Dormant Projects, H1 2017 (Contd..1), H1 2017 Autism - Discontinued Products, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: